Screener
Halozyme Therapeutics HALO Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Computer and office equipment | 6,965 | 8,034 |
| Internal-use software | 2,559 | 1,878 |
| Leasehold improvements | 7,521 | 7,521 |
| Subtotal | 83,700 | 77,601 |
| Accumulated depreciation and amortization | (33,936) | (33,159) |
| Subtotal | 49,764 | 44,442 |
| Right of use of assets | 34,507 | 37,695 |
| Total property and equipment, net | $84,271 | $82,137 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's cumulative cost basis?
- Halozyme Therapeutics (HALO) reported cumulative cost basis of $83.7M in Q2 2026.
- How has Halozyme Therapeutics's cumulative cost basis changed year-over-year?
- Halozyme Therapeutics's cumulative cost basis increased by 21.6% year-over-year, from $68.81M to $83.7M.
- What is the long-term trend for Halozyme Therapeutics's cumulative cost basis?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's cumulative cost basis has grown at a -18.8% compound annual growth rate (CAGR), from $220.22M to $77.6M.
- What does cumulative cost basis mean?
- The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.
Ask your AI about Halozyme Therapeutics's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude